• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Med-tech gainers and losers for April 27 - May 1, 2020

May 1, 2020
The top 10 med-tech stock gainers and losers for the week.
Read More

Biggest gainers and losers for the week of April 27-May 1, 2020

May 1, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More
Health professional reading lung scan

Biopharmas work to wallop COVID-19 respiratory effects, keeping patients off ventilators

April 28, 2020
By Karen Carey
Respiratory complications caused by COVID-19 can propel a patient from a mild cough one day to a ventilator and an ICU only 10 days later. As countries around the world work to stockpile ventilators and citizens continue social distancing measures, biopharma companies are tackling the development of fast-acting therapeutics to disrupt a dire disease trajectory in hospitalized patients. An industry-wide frantic race has ensued. On March 5, BioWorld reported that there were approximately 30 therapeutics and vaccines in development for COVID-19. As of April 28, there were 343 total: 249 therapeutics and 94 vaccines.
Read More
Antibodies
1+1=5

After a slow start, bispecific antibody space takes off

April 27, 2020
By Brian Orelli
Blincyto (blinatumomab, Amgen Inc.), the first FDA-approved bispecific antibody, gained regulatory approval in 2014, but the intervening years have been fairly bleak for bispecific antibodies as companies worked through technical challenges.
Read More

Week in review for April 20-24, 2020: Investors tracking companies developing therapies for cancer, neurological diseases

April 27, 2020
By Peter Winter
A quick look back at top stories.
Read More

Money raised by biopharma: 2020 vs. 2019

April 24, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-April 23, 2020

April 24, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Biopharmaceutical collaborations: March 2020

April 24, 2020
Biopharma licensings, joint ventures and collaborations, including: Alector, Allogene, Alnylam, Amgen, Astellas, Astrazeneca, Bayer, Biocon, Biofrontera, Biogen, Biontech, Brightinsight, Bristol-Myers Squib, Canndoc, Celator, Codexis, Cytomx, Cytori, Debiopharm, Eli Lilly, Emergent Biosolutions, Epivax, Evotec, Forge, Forma, Fujifilm, Fujitsu, Generex, Hoth, Hypera, Ideaya, I-Mab, Immix, Isoprene, Jiangsu Alphamab, Lonza, Mannkind, Medigene, Medivir, Merck, Merrimack, Mochida, Neurorx, Nicox, Novartis, Novavax, Novotech, Oasmia, Ono, Peptidream, Pfizer, Regeneron, Revive, Sanofi, Sciclone, Shionogi, Simcere, Sorrento, Sutro, Takeda, Trianni, Ultragenyx, Vaxart, Vir, Xencor, Xoma, Zai Lab.
Read More
Illustration of big fish eating three smaller fish

Completed biopharmaceutical mergers & acquisitions: March 2020

April 24, 2020
Completed biopharma M&As, including: Asahi Kasei, Axim, Danaher, Domain, Foamix, GE Healthcare, Menlo, Neurofit, Prestwick Chemical, Psilocin, Recode, Revive, Sapphire, Transcriptx, Veloxis.
Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: March 2020

April 24, 2020
Deals between biopharma companies and government or nonprofit entities, including: Acelrx, Allovir, Altimmune, Anabios, Arcturus, Astellas, Avectas, Berkeley Lights, Celldex, Cyclica, Daiichi Sankyo, Diverse, Dyadic, Grifols, Ideaya, IMV, Isoplexis, Janssen, Kuur, Lift, Lonza, Pluristem, Ridgeback, Shanghai Junshi, Sihuan, SK Chemicals, Themis, Wuxi Biologics, Zelluna, Ziphius.
Read More
Previous 1 2 … 223 224 225 226 227 228 229 230 231 … 261 262 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe